<DOC>
	<DOCNO>NCT01682187</DOCNO>
	<brief_summary>This study oral LY2157299 monotherapy combination lomustine participant recurrent malignant glioma .</brief_summary>
	<brief_title>A Dose-Escalation Study Participants With Recurrent Malignant Glioma</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<criteria>Have give write informed consent Have histological cytological evidence relapse malignant glioma ( glioblastoma multiforme , anaplastic astrocytoma , anaplastic oligodendroglioma ) treatment high priority exist Available baseline tumor specimen require prior consider participant enrol . The original diagnostic tumor tissue sufficient inclusion criterion , possible , freshly obtain tumor biopsy material may obtain Measurable disease allow assessment tumor response base radiographic assessment follow Macdonald criterion Response Evaluation Criteria In Solid Tumors ( RECIST ) Have sufficient hepatic , renal , hematological function Have performance status â‰¤2 Eastern Cooperative Oncology Group ( ECOG ) scale Have discontinue previous therapy cancer , include chemotherapy , radiotherapy investigational therapy least 30 day prior study enrollment recover acute effect therapy Able swallow tablet capsule For female , reproductive potential must either terminate ( surgery , radiation , menopause ) attenuate use approve contraceptive method ( include intrauterine barrier device ) 3 6 month study Male participant must willing use contraception 3 6 month study Have receive treatment within last 30 day drug receive regulatory approval indication time study entry Have moderate severe cardiac disease : Have presence cardiac disease , include myocardial infarction within 6 month prior study entry , unstable angina pectoris , New York Heart Association ( NYHA ) Class III/IV congestive heart failure , uncontrolled hypertension Have document major electrocardiogram ( ECG ) abnormalities investigator 's discretion ( example , symptomatic sustain atrial ventricular arrhythmia , second thirddegree atrioventricular block , bundle branch block , ventricular hypertrophy , recent myocardial infarction ) Have major abnormality document echocardiography Doppler ( example , moderate severe heart valve function defect and/or leave ventricular ejection fraction ( LVEF ) &lt; 50 % , evaluation base institutional low limit normal ) Have predispose condition consistent development aneurysm ascend aorta aortic stress ( example , family history aneurysm , Marfan syndrome , bicuspid aortic valve , evidence damage large vessel heart document computerized tomography [ CT ] scan contrast ) Have current acute chronic leukemia Women pregnant lactating Have receive prior nitrosourea ( include lomustine ) therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>